The Complete Guide to FDA 510(k) Submissions

What Is a 510(k)?

A 510(k) is a premarket notification submitted to the FDA to demonstrate that a medical device is substantially equivalent to a legally marketed device — known as a predicate — that was on the market before May 28, 1976, or that has itself been cleared through the 510(k) pathway. The name comes from Section 510(k) of the Federal Food, Drug, and Cosmetic Act.

This is the most common pathway to the US market for medical devices. The FDA clears roughly 3,000 to 3,500 510(k) submissions per year. It is not an "approval" — the FDA clears 510(k) devices by finding them substantially equivalent (SE) to a predicate. This distinction matters. PMA devices are approved. 510(k) devices are cleared. Using the wrong term signals to reviewers (and investors) that you do not understand the regulatory landscape.

A 510(k) clearance allows you to legally market your device in the United States. It does not, by itself, mean the device is safe and effective — it means the FDA has determined your device is as safe and effective as the predicate device already on the market.

When Do You Need a 510(k)?

Not every medical device requires a 510(k). The determination depends on device classification, exemption status, and whether a predicate exists.

You Need a 510(k) If:

• Your device is Class II (or Class I if not exempt) and you intend to market it in the US
• You are making a significant modification to a device you already have clearance for — a change in intended use, technology, materials, or design that could affect safety or effectiveness
• Your device is Class III but falls under a classification regulation that requires a 510(k) rather than a PMA (this is rare but does happen for certain pre-amendment Class III devices)

You Do NOT Need a 510(k) If:

• Your device is Class I exempt or Class II exempt from premarket notification (check the product classification database at accessdata.fda.gov)
• You are not introducing the device into commercial distribution (e.g., custom devices under Section 520(b), investigational use only)
• Your modification to a previously cleared device is not significant and you have documented this determination under your change management process

510(k) vs. Other FDA Pathways

Understanding where the 510(k) fits relative to other pathways is critical. Choosing the wrong pathway wastes months of work and significant money.

Factor	510(k)	De Novo	PMA
Device risk class	Class I (non-exempt), Class II	Novel Class I or II (no predicate)	Class III
Predicate required?	Yes	No (you become the predicate)	No
Standard of review	Substantial equivalence	Reasonable assurance of safety and effectiveness	Reasonable assurance of safety and effectiveness
Clinical data typically required?	Sometimes (depends on device type)	Often	Almost always
Average review time	~108–142 days (calendar, median)	~150–250 days	~12–18 months
User fee (FY2026)	$26,067 (standard) / $6,517 (small business)	$173,782 (standard) / $43,446 (small business)	$579,272 (standard) / $144,818 (small business)
Annual reporting	No	No	Yes (PMA annual report)
Post-clearance changes	New 510(k) or letter-to-file	New 510(k) or letter-to-file	PMA supplement

Practical tip: If your device is truly novel — no predicate exists — do not try to force-fit a 510(k). A reviewer will reject it at Refuse to Accept (RTA) or issue a Not Substantially Equivalent (NSE) determination. The De Novo pathway exists for exactly this scenario, and a successful De Novo creates a new classification regulation that future devices can use as a predicate.

Types of 510(k) Submissions

There are three types of 510(k) submissions, and choosing the right one can significantly affect your timeline and the depth of review.

Traditional 510(k)

The default submission type. You provide all the information needed to demonstrate substantial equivalence directly in the submission. This includes device description, intended use, comparison to predicate, performance testing data, biocompatibility data (if applicable), software documentation (if applicable), labeling, and sterilization information (if applicable).

When to use: Most first-time submitters use a Traditional 510(k). It is appropriate when no recognized consensus standard or FDA guidance covers the entirety of your testing requirements, or when you have test data that does not align cleanly with a guidance or standard.

Special 510(k)

Designed for modifications to your own previously cleared device. A Special 510(k) relies on your quality system (design controls) to evaluate the change rather than providing full test data in the submission. You submit a summary of the design control process, risk analysis, and verification/validation activities that demonstrate the modification does not affect safety or effectiveness.

When to use: When you are modifying a device for which you already hold a 510(k) clearance and can demonstrate through your design controls that the change does not raise new questions of safety or effectiveness. The FDA's goal review time for Special 510(k)s is 30 days — significantly faster than the Traditional pathway.

Key limitation: You cannot use a Special 510(k) if the modification changes the device's intended use, and you cannot reference someone else's device as the predicate — only your own.

Abbreviated 510(k)

Relies on conformance to FDA-recognized consensus standards or FDA guidance documents to demonstrate substantial equivalence. Instead of submitting full test data, you provide a declaration of conformity to the applicable standard(s) and/or a summary report referencing the guidance.

When to use: When recognized consensus standards (e.g., IEC 60601-1 for electrical safety, ISO 10993 series for biocompatibility, IEC 62304 for software lifecycle) or FDA-specific guidance documents cover the performance requirements for your device type. This pathway can streamline the submission substantially if the standards are well-suited to your device.

Comparison of 510(k) Types

Feature	Traditional	Special	Abbreviated
Predicate	Any legally marketed device	Your own previously cleared device	Any legally marketed device
Performance data	Included in full	Summarized via design controls	Declaration of conformity to standards
FDA review goal	90 days (MDUFA)	30 days	90 days (MDUFA)
Best for	First-time submissions, novel testing	Modifications to your own device	Devices with strong standard coverage
Can change intended use?	Yes	No	Yes
Submission volume	~70% of all 510(k)s	~10%	~20%

Real-World Scenarios: Choosing the Right 510(k) Type

Scenario 1 — Traditional 510(k): A startup is bringing a novel wearable continuous glucose monitor to market. This is their first device and they are referencing a competitor's cleared CGM as the predicate. They have new sensor chemistry that requires full biocompatibility and performance testing. A Traditional 510(k) is the only option — they do not own a prior clearance (ruling out Special) and the novel sensor technology means standards alone do not cover their testing needs (ruling out Abbreviated).

Scenario 2 — Special 510(k): A company that already holds clearance for an infusion pump (K192345) wants to update the pump's user interface software. The intended use is unchanged, the hardware is unchanged, and the software change was evaluated through their design control process with updated risk analysis and software V&V. A Special 510(k) referencing their own K192345 as the predicate is ideal — they can expect a 30-day review.

Scenario 3 — Abbreviated 510(k): A manufacturer of conventional Foley catheters wants to introduce a new catheter size. FDA-recognized consensus standards (ASTM, ISO) and the device-specific FDA guidance cover all performance requirements for this well-established device type. An Abbreviated 510(k) with declarations of conformity to recognized standards streamlines the submission. This device may also qualify for the Safety and Performance Based Pathway (discussed below).

Safety and Performance Based Pathway

The Safety and Performance Based Pathway is a variant of the Abbreviated 510(k) introduced by the FDA to accelerate clearance for well-understood device types. Instead of requiring a direct side-by-side comparison with a predicate, manufacturers demonstrate that their device meets FDA-published performance criteria specific to the device category.

How it works:

• The FDA publishes final guidance documents that define safety and performance criteria for specific device types
• You still identify a predicate device, but you do not need to provide traditional comparative testing
• Instead, you demonstrate conformance to the FDA's established performance benchmarks
• You submit through the eSTAR as an "Abbreviated" 510(k) and note in your cover letter that you are using the Safety and Performance Based Pathway

Eligible device types (as of early 2026 — the FDA continues expanding this list):

• Conventional Foley catheters
• Dental handpieces, cements, ceramics, impression materials, and implant abutments
• Orthopedic bone screws, fixation plates, and spinal pedicle screw systems
• Surgical sutures
• Contact lenses (certain types)
• Electrodes and MRI RF coils

Benefits: Potentially faster review, reduced testing burden, and clearer expectations. The 90-day MDUFA review goal applies, and submissions through this pathway tend to have lower AI request rates because the performance criteria are well-defined.

Practical tip: Check the FDA's Safety and Performance Based Pathway page for the current list of eligible device types and associated guidance documents. If your device falls into one of these categories, this pathway can save significant time and testing expense.

Predicate Device Selection Strategy

Predicate selection is arguably the single most important strategic decision in the 510(k) process. A poorly chosen predicate leads to comparison challenges, additional testing requirements, or outright rejection.

What Makes a Valid Predicate?

A valid predicate must be a legally marketed device that is either:

1. A pre-amendment device — on the market before May 28, 1976
2. A device previously cleared through 510(k)
3. A device reclassified from Class III to Class II or I through De Novo

A device that has been recalled, withdrawn from the market, or found to be NSE can still serve as a predicate — what matters is whether it was legally marketed at some point. However, using a recalled device as a predicate invites questions from reviewers, so avoid it unless there is a compelling reason.

Primary vs. Reference Predicates

• Primary predicate: The single device to which you claim substantial equivalence. Your intended use must be the same (or a subset of) the primary predicate's intended use, and you must demonstrate technological equivalence.
• Reference predicate: Additional legally marketed devices you reference to support specific aspects of your comparison — for example, to show that a particular technology or material has been previously cleared for a similar application. Reference predicates support your argument but are not the basis of the SE determination.

How to Search FDA Databases for Predicate Devices

Finding the right predicate requires systematic use of several FDA databases. Here is a step-by-step approach:

Step 1 — Identify your product code. Go to the FDA Product Classification Database (accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm). Search by device name or description. The product code (a three-letter code like "QKQ" for pulse oximeters or "DXN" for orthopedic screws) determines your classification panel, special controls, and the review division that will handle your submission.

Step 2 — Search the 510(k) Premarket Notification database. Go to accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. The most effective search strategy is to search by product code — this returns all 510(k) clearances in your device category. Tips for effective searching:

• Search by product code first. This is more reliable than keyword searching because the database matches exact text.
• Enter only one search field at a time. The search engine looks for exact matches, so filling multiple fields simultaneously often returns zero results.
• If searching by device name, use a single descriptive keyword rather than a full device name.
• Sort by decision date (newest first) to find recent predicates.

Step 3 — Review the 510(k) summary documents. For each promising predicate, click through to download the 510(k) Summary (if available). These summaries are public and reveal the predicate's intended use statement, what testing the FDA reviewed, which standards were cited, and the basis for the SE determination.

Step 4 — Cross-reference with the GUDID. The Global Unique Device Identification Database (accessgudid.nlm.nih.gov) provides additional device information including brand names, device identifiers, company contacts, and device characteristics. This is useful when you know a competitor's commercial product name but not their 510(k) number.

Step 5 — Check the FDA MAUDE database. The Manufacturer and User Facility Device Experience database (accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm) contains adverse event reports. Searching for potential predicates in MAUDE reveals any safety signals — information you need before committing to a predicate.

Step 6 — Review the FDA Recall database. Search the FDA's recall database for any Class I, II, or III recalls associated with potential predicates. A predicate with a recall history is still legally valid, but it may invite additional scrutiny.

Pro tip: Use FOIA (Freedom of Information Act) requests to obtain the full review memorandum for a predicate device. The review memo contains the FDA reviewer's detailed analysis and is far more informative than the public 510(k) summary. FOIA requests are free but may take several months.

Predicate Selection Best Practices

1. Search the 510(k) database thoroughly. Use the FDA's 510(k) Premarket Notification database (accessdata.fda.gov) and filter by product code, applicant, and date. Also search the predicate's summary or statement of SE — these are public and reveal what testing the FDA found acceptable.

2. Match intended use first, technology second. The FDA's SE analysis starts with intended use. If the intended use differs from the predicate, you fail the first gate and need to provide clinical data or choose a different predicate. Technology differences are more forgivable if the intended use is identical.

3. Prefer recent predicates. A predicate from 2020 is better than one from 1998. Older predicates may reference outdated standards, and reviewers may question whether the comparison is meaningful. Newer predicates also give you more information — recent 510(k) summary documents are more detailed.

4. Prefer predicates with public summaries. If the predicate holder submitted a Summary (rather than a Statement), you can read exactly what testing was done, what standards were cited, and what the SE rationale was. This is a goldmine for planning your own submission.

5. Check for enforcement actions. If the predicate device has been subject to a Warning Letter, consent decree, or significant recall, think carefully before relying on it. It is still a valid predicate, but reviewers may scrutinize your submission more closely.

6. Avoid "predicate creep." This is the practice of chaining predicates across many generations to argue that a modern device is substantially equivalent to something from 1976. The FDA has become increasingly skeptical of long predicate chains, especially when accumulated differences are significant. Keep your comparison direct.

Real-world example: A company developing a new pulse oximeter might choose a recently cleared competitor's pulse oximeter as the primary predicate (same intended use, same basic technology) and reference an older predicate that uses the same novel sensor material to demonstrate that the material itself has been previously cleared.

Real Examples of Successful 510(k) Clearances

Studying actual cleared 510(k)s is one of the best ways to understand what the FDA expects. Here are examples across different device types that illustrate different strategies:

Example 1 — AI/ML Software Device (Radiology): In 2024–2025, the FDA cleared over 295 AI/ML-enabled medical devices through the 510(k) pathway, many in radiology. A typical submission in this category references a predicate AI software device with the same intended use (e.g., computer-aided detection of pulmonary nodules), provides standalone clinical performance data (sensitivity, specificity, AUC), and includes comprehensive software documentation per IEC 62304 and the FDA's software guidance. These clearances demonstrate that even cutting-edge technology can go through 510(k) when a suitable predicate exists.

Example 2 — Orthopedic Implant (Spinal Pedicle Screw System): Spinal pedicle screw systems are one of the most frequently cleared device types. A successful submission typically references a recently cleared predicate from the same product code (e.g., product code MNH), provides mechanical testing (static and fatigue testing per ASTM F2193 and ASTM F1717), biocompatibility evaluation per ISO 10993-1, and sterilization validation. Many recent clearances in this category have used the Abbreviated 510(k) pathway with declarations of conformity to recognized standards.

Example 3 — Connected Digital Health Device: A wireless blood pressure monitor cleared through 510(k) in 2024 referenced a previously cleared digital sphygmomanometer as the predicate. The submission included standard performance testing (accuracy per ISO 81060-2), electrical safety and EMC testing (IEC 60601-1, IEC 60601-1-2), cybersecurity documentation per the FDA's 2023 cybersecurity guidance (addressing SBOM, threat modeling, and security architecture), and wireless coexistence testing. This example shows the increasing cybersecurity documentation burden for connected devices.

Example 4 — Simple Class II Device (Surgical Instrument): A new design of surgical forceps cleared via Traditional 510(k) with a straightforward submission: device description, comparison to a cleared forceps predicate, mechanical performance testing (grip force, fatigue), biocompatibility evaluation (limited testing due to well-characterized stainless steel), and sterilization validation. Total FDA review time: under 60 days with no AI requests. Simple devices with well-matched predicates and complete submissions can clear quickly.

Where to study real clearances: The FDA publishes all 510(k) clearance decisions at accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. For recent CBER-regulated devices (blood-related, certain tissue products), cleared 510(k) summaries with full supporting documents are available on the FDA's Vaccines, Blood & Biologics page. Reviewing 5–10 recent clearances in your product code before starting your submission is one of the highest-value activities you can do.

Understanding Substantial Equivalence

The legal standard for 510(k) clearance is "substantial equivalence." This does not mean identical — it means substantially equivalent in terms of intended use, design, materials, and performance.

The SE Flowchart

The FDA follows a defined decision tree:

1. Same intended use? — If no, the device is NSE. Full stop. (Unless you provide clinical data showing the new intended use does not raise different questions of safety and effectiveness.)
2. Same technological characteristics? — If yes, and same intended use, the device is SE. You are done.
3. Different technological characteristics? — If yes, do the differences raise new questions of safety or effectiveness?
   • If no, the device is SE.
   • If yes, can you provide data (bench, animal, clinical) to demonstrate the device is as safe and effective as the predicate? If yes, SE. If no, NSE.

What "Intended Use" Really Means

Intended use encompasses:

• The disease or condition the device diagnoses, treats, prevents, mitigates, or cures
• The patient population (pediatric vs. adult, specific clinical settings)
• The part of the body the device contacts or acts upon
• The clinical context (professional use, home use, over-the-counter)

The intended use must be the same as (or a subset of) the predicate's. Expanding intended use beyond the predicate's is the single fastest way to get an NSE determination.

Technological Characteristics

These include:

• Materials and material composition
• Design and engineering specifications
• Energy source and type
• Software algorithms and functionality
• Manufacturing processes that affect device performance

Different technological characteristics are acceptable as long as they do not raise different questions of safety or effectiveness — or if they do, you have data to resolve those questions.

The 510(k) Submission Process: Step by Step

Step 1: Device Classification and Regulatory Strategy

Before writing a single word of your submission, determine:

• Product code — Use the FDA Product Classification Database. The product code dictates which review division will handle your submission, what standards apply, and what special controls exist.
• Classification regulation — The 21 CFR regulation that describes your device type and its classification.
• Applicable guidance documents — Check the FDA guidance database for device-specific guidance. These are not legally binding but represent the FDA's current thinking and are treated as a roadmap by reviewers.
• Recognized consensus standards — Check the FDA's Recognized Consensus Standards Database for standards applicable to your device type.
• Predicate device(s) — Identify your primary and reference predicates.

Step 2: Pre-Submission Meeting (Optional but Highly Recommended)

A Pre-Submission (Pre-Sub) is a formal meeting request to the FDA review division. You submit a package outlining your device, your proposed predicate, your testing plan, and specific questions. The FDA responds in writing and may schedule a meeting (in-person, teleconference, or written-only).

Why this is worth your time:

• You get written FDA feedback on your predicate selection before committing to a strategy
• You learn what testing the FDA expects — and what they do not need
• You avoid surprises during review
• The feedback letter becomes part of your file and can be referenced in your submission

Pre-Sub tips:

• Ask specific, answerable questions. "Is my predicate acceptable?" is a good question. "What should I test?" is too vague.
• Provide enough technical detail for the FDA to give meaningful feedback. Attach your proposed test protocols if possible.
• Allow 75 days from submission of the Pre-Sub request to the meeting date.

Step 3: Testing and Data Generation

Based on your regulatory strategy (and ideally Pre-Sub feedback), execute your testing program. Common categories include:

Performance testing (bench testing)

• Mechanical testing (tensile strength, fatigue, dimensional accuracy)
• Electrical safety and EMC testing (IEC 60601-1, IEC 60601-1-2)
• Chemical characterization
• Shelf life/stability testing
• Sterility assurance (if applicable)

Biocompatibility testing

• Follow the ISO 10993 series and FDA's biocompatibility guidance
• Conduct a biological evaluation per ISO 10993-1 — this may or may not result in actual testing depending on your material characterization
• Common endpoints: cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation (for implants), hemocompatibility (for blood-contacting devices)

Software documentation (if applicable)

• Software level of concern or safety classification per IEC 62304
• Software description and architecture
• Software requirements specification (SRS)
• Verification and validation testing
• Cybersecurity documentation per FDA cybersecurity guidance (for connected devices)
• Follow the latest FDA guidance on Content of Premarket Submissions for Device Software Functions

Clinical data (if required)

• Not all 510(k)s require clinical data, but some device types do
• Check the device-specific guidance for clinical data expectations
• Clinical data can come from clinical studies, published literature, or clinical experience with the predicate

Sterilization validation (if applicable)

• Sterility assurance level (SAL) demonstration
• Bioburden testing
• Sterilization validation per the relevant ISO standard (ISO 11135 for EO, ISO 11137 for radiation, ISO 17665 for steam)
• Residual analysis for EO-sterilized devices

Step 4: Prepare the Submission Document

A 510(k) submission has a defined structure. Since 2023, the FDA requires electronic submissions through the eSTAR (electronic Submission Template And Resource) system for all 510(k)s. More on eSTAR below.

The core sections of a 510(k) are:

Section	Description
Cover letter	Identifies the submission type, device name, applicant, and contact information
MDDT/eSTAR cover sheet	Administrative information in the eSTAR format
Truthful and Accurate Statement	Signed statement that the information is truthful and accurate
Table of Contents	Organized listing of all sections and attachments
Indications for Use Statement	FDA Form 3881 — the precise intended use and indications for use
510(k) Summary or Statement	Either a summary of SE basis (made public) or a statement that safety/effectiveness data will be made available upon request
Device Description	Detailed description of the device, its components, accessories, and principles of operation
Substantial Equivalence Comparison	Side-by-side comparison of your device to the predicate — intended use, technological characteristics, and performance
Performance Testing	All bench, biocompatibility, software, electrical safety, and sterilization testing results
Biocompatibility	Biological evaluation per ISO 10993-1 and any test reports
Software Documentation	Software description, level of concern, V&V results, cybersecurity documentation
Sterility	Sterilization method validation and results
Labeling	Draft device labeling including instructions for use, warnings, contraindications
Electromagnetic Compatibility (EMC)	IEC 60601-1-2 test results for electrical/electronic devices
Clinical Data	Clinical studies, literature review, or clinical experience data (if applicable)

Step 5: eSTAR Submission

Since October 2023, the FDA requires all 510(k) submissions to use the eSTAR template. This replaced the old eCopy process. As of October 2025, eSTAR is also mandatory for De Novo submissions.

What is eSTAR?

eSTAR is an interactive PDF template that guides you through every section of the 510(k). It includes built-in logic — depending on your device type and answers to earlier questions, the template will expand or collapse sections to show only what is relevant.

Which eSTAR template do you need?

The FDA publishes three eSTAR template variants:

1. Non-In Vitro Diagnostic (nIVD) eSTAR — For 510(k), De Novo, and PMA submissions for most medical devices. Currently on Version 6 (updated February 2026).
2. In Vitro Diagnostic (IVD) eSTAR — For 510(k), De Novo, and PMA submissions for IVD devices. Also Version 6.
3. PreSTAR — For Pre-Submissions, IDEs, and 513(g) requests. Version 2.

Download the correct template from the FDA's eSTAR Program page. Always check for the latest version before starting — the FDA updates templates periodically (most recently in February 2026 to align with the new QMSR regulation and updated Real-World Evidence guidance).

eSTAR Section-by-Section Walkthrough (nIVD Template)

The nIVD eSTAR template is organized into the following major sections. As you answer questions in the template, sections will dynamically expand or collapse based on relevance to your device:

eSTAR Section	What Goes Here	Key Tips
Administrative Information	Applicant name, contact info, submission type, establishment registration number. Integrates FDA Form 3514 (cover sheet) automatically.	Double-check that your establishment registration is current. The template auto-fills some fields.
Indications for Use	FDA Form 3881 is integrated into the template. Enter your precise intended use and indications for use statement.	This is the single most scrutinized field. Ensure it matches your labeling, device description, and predicate comparison exactly. Inconsistencies here are a top RTA trigger.
Truthful and Accurate Statement	Certification that the submission is truthful and accurate. Integrated into the template — no separate letterhead needed.	Simply complete the fields. This replaced the old requirement for a separate signed statement on company letterhead.
510(k) Summary or Statement	Choose whether to provide a Summary (made public) or a Statement. The eSTAR generates the Summary from information entered in other sections.	Choose Summary. It is standard practice and signals confidence. The template auto-generates a draft based on your other entries.
Device Description	Detailed description of the device, principles of operation, components, accessories, and system/kit information.	Be thorough. Include materials, dimensions, energy source, and how the device works. The "System/Kit Components and Accessories" subsection at the end is frequently missed.
Substantial Equivalence Comparison	Side-by-side comparison to the predicate. Predicate identification, intended use comparison, technological characteristics comparison.	The template provides structured fields for each comparison element. Fill every field — do not leave blanks.
Standards and Guidance	Declaration of conformity to recognized consensus standards. References to FDA guidance documents.	The eSTAR includes a link to the FDA's Recognized Consensus Standards Database. Select the exact edition of each standard you tested to.
Performance Testing — Bench	Bench test results, acceptance criteria, and summary of findings for mechanical, chemical, and other performance tests.	Attach full test reports as PDFs. Provide a clear summary in the template fields explaining what was tested, the acceptance criteria, and whether the device passed.
Biocompatibility	Biological evaluation per ISO 10993-1, risk assessment, chemical characterization, and any biological test reports.	The template prompts for body contact type and contact duration, then dynamically shows which endpoints are expected. Respond to every prompt.
Sterility / Sterilization	Sterilization method, validation data, bioburden, residuals (for EO), package integrity testing, shelf life/stability.	The template includes updated prompts for pyrogenicity testing options and EtO residuals. Do not skip the packaging validation subsection.
Software Documentation	Software level of concern or safety classification (per IEC 62304), architecture, requirements, V&V, SOUP (Software of Unknown Provenance) list, cybersecurity documentation.	The SOUP inventory is a frequent gap. List every third-party software component. Cybersecurity documentation requirements have expanded significantly — follow the FDA's 2023 cybersecurity guidance for connected devices.
Electromagnetic Compatibility (EMC)	IEC 60601-1-2 test results, applicable collateral and particular standards.	Ensure test reports cover the current edition of the standard (Edition 4.1 as of 2026). Include all relevant test configurations.
Clinical Data	Clinical studies, literature reviews, clinical experience data. Only visible if you indicate clinical data is included.	If your device-specific guidance calls for clinical data, include it even if you believe bench data is sufficient — omitting it is an AI request trigger.
Labeling	Draft IFU, labels, packaging, marketing materials. All warnings, contraindications, and precautions.	Submit complete draft labeling. Include the UDI (Unique Device Identifier) format on the label. Ensure every warning in your risk analysis appears in the labeling.

Key eSTAR technical details:

• File size limits: The CDRH Portal accepts eSTARs up to 4 GB total, with individual attachments capped at 1 GB each. For CBER submissions through the Electronic Submission Gateway (ESG), the limit is 100 GB. If your eSTAR exceeds 4 GB, follow the instructions on the CDRH Portal website for oversized submissions.
• Software requirement: You must use Adobe Acrobat Pro (not a web browser). The eSTAR template will not function correctly in Edge, Chrome, Firefox, or Safari. If the template runs slowly, disable Protected Mode in Acrobat Pro settings.
• Supported attachment formats: PDF (non-password-protected), JPEG, AVC MP4, HEVC MP4. Use HEVC compression for video files.
• Built-in forms: The eSTAR integrates Form 3514 (cover sheet), Form 3881 (indications for use), the Truthful and Accurate Statement, and the Declaration of Conformity. Do not submit these as separate documents — the eSTAR generates them.
• Validation function: Before submission, use the eSTAR's built-in completeness check. The template must reach "eSTAR Complete" status before you submit. Incomplete eSTARs will be rejected at the portal level.
• Submission portal: For CDRH devices, submit through the CDRH Customer Collaboration Portal. For CBER devices, submit through the FDA Electronic Submission Gateway (ESG).

eSTAR tips:

• Do not fight the template. Answer every question. If a section is not applicable, mark it N/A and explain why.
• Attach supporting documents in the order the template references them.
• Name attachments clearly. "Appendix_A_Biocompatibility_Report.pdf" is better than "Report_Final_v3_FINAL.pdf."
• The eSTAR template does not support multiple simultaneous users, tracked changes, or collaborative editing. Plan your workflow accordingly — one person should own the eSTAR file, with other team members providing content in separate documents that get integrated.
• Review the FDA's eSTAR training resources — they publish tutorial videos and FAQs.
• Run a completeness check before submission. The eSTAR template has a built-in validation function.
• Read the Introduction, Key, FAQ, and Version History sections within the template itself before starting — these contain important instructions specific to the current version.

Common eSTAR mistake: Submitting separate copies of Form 3881, Form 3514, or the Truthful and Accurate Statement alongside the eSTAR. These forms are integrated into the template. Submitting them separately creates confusion and may trigger an RTA hold for inconsistencies.

Step 6: Submit and Pay the User Fee

Submit your eSTAR package through the FDA portal. You must pay the user fee before or at the time of submission — your 510(k) will not be processed until the fee is received.

Step 7: FDA Review

Once submitted, your 510(k) enters the FDA review process, which has several defined phases.

FDA Review Timeline and Process

The FDA review process for a Traditional 510(k) follows this general timeline:

Phase 1: Acceptance Review (RTA — Refuse to Accept)

Timeline: Day 1 – Day 15

The FDA conducts an administrative review to determine whether the submission is complete enough to accept for substantive review. This is the Refuse to Accept (RTA) screening. The FDA checks:

• Is the eSTAR template complete?
• Are all required sections present?
• Is the user fee paid?
• Are labeling drafts included?
• Is the Indications for Use statement (Form 3881) included and consistent with the submission?
• Is there a clear predicate identified?
• Is there a SE comparison?

If the submission fails RTA, the FDA issues a Refuse to Accept letter identifying the deficiencies. You can either withdraw and resubmit (filing a new submission with a new user fee) or address the deficiencies and request the FDA reconsider within a limited timeframe.

Important: RTA rejection rates are alarmingly high. Industry data suggests that approximately 58–69% of 510(k) submissions receive an RTA hold or refusal on initial screening. Although there are 43 specific checkpoints in the FDA's 35-page RTA checklist, roughly 80% of refusals stem from about 20% of the reasons — primarily missing or inconsistent Indications for Use statements, inadequate SE comparison tables, missing labeling, and incomplete eSTAR fields. This is the single biggest avoidable delay. Use the FDA's RTA acceptance checklist (available on fda.gov for each submission type) and review your submission against it line-by-line before filing. A former FDA reviewer recommends including a completed copy of the RTA checklist with your submission, noting the page numbers where each item is addressed — this helps the FDA screener verify completeness quickly and reduces the chance of an erroneous RTA hold.

Phase 2: Substantive Review

Timeline: Day 15 – Day 90 (goal)

The assigned reviewer conducts a detailed review of the submission. They evaluate:

• Whether the predicate is valid
• Whether the intended use comparison is appropriate
• Whether the technological comparison is complete
• Whether the performance data supports SE
• Whether the labeling is adequate

Phase 3: Interactive Review / Additional Information Request

Timeline: Variable (adds 90–180+ days in practice)

If the reviewer has questions, they issue an Additional Information (AI) request. This pauses the review clock. You typically have 180 days to respond. If you do not respond within 180 days, the FDA considers the submission withdrawn.

AI requests are common — more than half of 510(k)s receive at least one. The key is to respond completely. Partial responses lead to second and third AI requests, compounding delays.

Phase 4: Decision

Timeline: Within 90 days of last review cycle

The FDA issues one of three determinations:

• Substantially Equivalent (SE) — Your device is cleared for marketing. You receive a clearance letter with a 510(k) number (e.g., K240001).
• Not Substantially Equivalent (NSE) — Your device is not SE to the predicate. You cannot market the device under this clearance. Options include resubmitting with a different predicate, pursuing De Novo classification, or submitting a PMA.
• Withdrawal — You voluntarily withdraw the submission (e.g., to resubmit with better data or a different strategy).

Realistic Total Timeline

Scenario	Approximate Calendar Time
Best case (no AI requests, clean submission)	3–4 months
Typical case (one AI request)	6–9 months
Difficult case (multiple AI requests, panel-track)	12–18 months
Special 510(k) (clean submission)	1–2 months

The MDUFA (Medical Device User Fee Amendments) performance goal for Traditional 510(k) review is 90 FDA days, but this clock stops during AI requests. Calendar time is always longer than FDA review days.

Current FDA Review Performance (MDUFA V Data)

The FDA publishes quarterly MDUFA performance reports. Here are the most recent data points:

• Median FDA review time for 510(k)s: Dropped from 120 days in 2022 to approximately 108 days in 2024. The 2025 median was approximately 142 days (calendar time including AI response periods), with an average of 150 days.
• MDUFA V Total Time to Decision goal for 510(k)s: 112 calendar days for FY2025 and FY2026. This is a shared outcome goal measuring the total time from submission to decision, including both FDA review time and sponsor response time.
• Fastest clearances: Approximately 25% of 510(k) submissions in 2025 were cleared in under 90 calendar days, demonstrating that well-prepared submissions with no AI requests can move very quickly.
• Biocompatibility-related delays: Submissions with biocompatibility deficiencies add approximately 25 additional days to the review timeline on average.
• Cybersecurity-related delays: Software/cybersecurity questions add approximately 18 additional days on average.

The FDA's MDUFA V performance reports are published on fda.gov under "FDA-TRACK" and provide the most current data on review timelines, AI request rates, and decision outcomes.

User Fees

510(k) user fees are set annually under MDUFA V and adjusted for inflation. The FDA publishes updated fee amounts each July in the Federal Register for the upcoming fiscal year (October 1 – September 30). The following table shows FY2026 fees as published by the FDA on July 30, 2025 (always verify the current year's fees on fda.gov, as they change annually).

Fee Type	Standard Fee	Small Business Fee
510(k) (Traditional, Special, or Abbreviated)	$26,067	$6,517
De Novo Classification Request	$173,782	$43,446
PMA / BLA	$579,272	$144,818
PMA Panel-Track Supplement	$463,418	$115,855
PMA 180-Day Supplement	$86,891	$21,723
PMA Real-Time Supplement	$40,549	$10,137
513(g) Request for Information	$7,820	$3,910
Annual Periodic Reporting (Class III)	$20,275	$5,069
Establishment Registration (annual)	$11,423	$11,423

Note: FY2026 fees represent notable increases over FY2025. The 510(k) small business fee increased approximately 7% from $6,084, and the establishment registration fee increased 23% from $9,280.

Fee notes:

• Small business qualification requires gross receipts or sales of $100 million or less. You must submit the Small Business Qualification and Certification form prior to or concurrent with the 510(k). Qualification is verified annually.
• Fees must be paid before the submission will be accepted for review
• Fees are non-refundable if the submission is filed, even if you later withdraw
• If the FDA refuses to accept (RTA) your submission and you resubmit, you must pay a new user fee — another reason to get it right the first time
• There is no user fee for a Pre-Submission (Pre-Sub) — this is free, which is another reason to use it
• The establishment registration fee ($11,423/year) is separate from the submission fee and must be paid annually to maintain your facility registration. This is required regardless of how many devices you market.

Common Deficiencies and RTA Issues

After reviewing thousands of FDA feedback letters and working with dozens of submitters, certain deficiency patterns appear repeatedly. Avoiding these will dramatically improve your chances of a clean review.

Top RTA (Refuse to Accept) Issues

1. Missing or incomplete Indications for Use statement (Form 3881). This must be signed, must match the intended use described in the submission, and must use precise language. Vague indications like "for general diagnostic purposes" will be rejected.

2. Inadequate SE comparison table. The side-by-side comparison must address every meaningful characteristic — intended use, technology, materials, performance specifications, dimensions, energy source, and so on. A superficial comparison table with "same" in every cell is a red flag.

3. Missing labeling. You must submit draft labeling, including the instructions for use (IFU), at the time of filing. "Labeling to be provided later" is not acceptable.

4. eSTAR template errors. Incomplete fields, missing attachments, or using an outdated version of the eSTAR template.

5. Incorrect predicate. Citing a predicate that was never cleared, has a different product code without explanation, or has a fundamentally different intended use.

6. Missing performance data. Submitting without test data or with data that does not address the key performance characteristics. Even if your testing is ongoing, do not submit until it is complete.

7. "I promise" statements instead of actual data. The FDA no longer accepts statements like "sterilization validation will be completed prior to marketing" or "biocompatibility testing is in progress." All testing data must be complete and included at the time of submission. This is a significant change from past practice — years ago, the FDA sometimes accepted commitments to complete testing, but current RTA screening rejects any submission with incomplete data.

8. Inconsistent Indications for Use across the submission. The IFU statement on Form 3881 must match the intended use in the device description, the SE comparison, the labeling, and the 510(k) summary — word for word. Reviewers check for consistency across all sections, and even minor wording differences (e.g., "monitoring" vs. "continuous monitoring") can trigger an RTA hold or AI request.

Top Substantive Review Deficiencies

1. Biocompatibility gaps. The most common substantive deficiency. Failures include: not conducting a biological evaluation per ISO 10993-1, missing endpoints for the device's body contact category and duration, using outdated standards, or referencing material "equivalence" without adequate chemical characterization to support it.

2. Software documentation deficiencies. Insufficient hazard analysis, missing or incomplete software requirements traceability, inadequate cybersecurity documentation for network-connected devices, or failure to follow the current FDA software guidance.

3. Sterilization validation issues. Incomplete validation of the sterilization process, missing bioburden data, insufficient residual EO analysis, or inadequate package integrity testing.

4. Electrical safety and EMC. Testing to outdated editions of IEC 60601-1 or IEC 60601-1-2, missing particular standards (collateral or particular standards applicable to the device type), or test reports that do not cover all relevant test conditions.

5. Labeling deficiencies. Missing required warning statements, contraindications that do not match the risk analysis, inadequate IFU, or inconsistencies between the IFU and the submission's device description.

6. Insufficient shelf life data. Relying solely on accelerated aging without a plan for real-time aging, or using inappropriate acceleration factors.

7. Clinical data gaps. When clinical data is expected (based on the device type or guidance document) and the submitter provides only bench data or an inadequate literature review.

The Substantial Equivalence Comparison: Getting It Right

The comparison table is the heart of the submission. Here is what a well-structured comparison looks like.

Structure of an Effective SE Comparison

Characteristic	Subject Device	Predicate Device (K######)	Comparison
Intended use / Indications for use	[Specific statement]	[Specific statement from predicate's clearance]	Same / Subset of predicate
Device description	[Detailed description]	[Description from predicate summary]	Similar — differences described below
Technology / Mechanism of action	[Description of how it works]	[Description]	Same fundamental technology
Materials (patient-contacting)	[List specific materials]	[List materials]	Same / Different — biocompatibility data provided
Materials (non-patient-contacting)	[List]	[List]	Same / Similar
Energy source	[Type, parameters]	[Type, parameters]	Same / Similar
Software	[Version, functions, classification]	[Version, functions]	Similar — software documentation provided
Dimensions / Size range	[Specific dimensions]	[Specific dimensions]	Within range of predicate
Sterilization	[Method]	[Method]	Same / Different — validation data provided
Shelf life	[Duration]	[Duration]	Same / Similar — stability data provided
Performance specifications	[Key specs with values]	[Key specs with values]	Equivalent — testing data provided
Biocompatibility	[Contact type, duration]	[Contact type, duration]	Same category — evaluation provided
Labeling	[Summary of key labeling elements]	[Summary]	Similar — all required elements included

Tips for the comparison:

• Never just write "same" without specifics. If the materials are the same, name them. If the dimensions are similar, provide the numbers.
• Be honest about differences. Reviewers respect transparency. Trying to hide a difference only to have the reviewer discover it during review destroys credibility and triggers deeper scrutiny of everything else.
• For every difference identified, explain why it does not raise new questions of safety or effectiveness, and point to the supporting data in your submission.

FDA Guidance Documents You Should Know

The FDA publishes guidance documents specific to the 510(k) process. These are essential reading:

Guidance Document	What It Covers
The 510(k) Program: Evaluating Substantial Equivalence	The FDA's framework for how they evaluate SE — the foundational document
Refuse to Accept Policy for 510(k)s	The criteria FDA uses during RTA screening — use this as your pre-submission checklist
Content of Premarket Submissions for Device Software Functions	Software documentation requirements — updated regularly
Deciding When to Submit a 510(k) for a Change to an Existing Device	Decision framework for whether a modification to a cleared device requires a new 510(k)
Use of International Standard ISO 10993-1	Biocompatibility evaluation framework
Cybersecurity in Medical Devices	Cybersecurity documentation requirements for connected devices
Recommendations for Clinical Data in Premarket Notification (510(k)) Submissions	When and what clinical data FDA expects
eSTAR Resources and Training	How to use the eSTAR template — tutorials, FAQs, and example completed templates

Additionally, check for device-specific guidance documents. For many product codes, the FDA has published guidance that specifies exactly what testing and documentation they expect. Finding and following the device-specific guidance is one of the highest-leverage activities in the entire submission process.

Key FDA guidance document links (all available at fda.gov/regulatory-information/search-fda-guidance-documents):

• The 510(k) Program: Evaluating Substantial Equivalence — fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k
• Refuse to Accept Policy for 510(k)s — fda.gov/regulatory-information/search-fda-guidance-documents/refuse-accept-policy-510ks
• Best Practices for Selecting a Predicate Device — fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-selecting-predicate-device-support-premarket-notification-510k-submission
• Deciding When to Submit a 510(k) for a Change to an Existing Device — fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-change-existing-device-510k
• Content of Premarket Submissions for Device Software Functions — fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-management-cybersecurity-medical-devices
• Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions — fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions
• Safety and Performance Based Pathway — fda.gov/regulatory-information/search-fda-guidance-documents/safety-and-performance-based-pathway
• Acceptance Checklists for 510(k)s — fda.gov/medical-devices/premarket-notification-510k/acceptance-checklists-510ks

510(k) Third Party Review Program

The 510(k) Third Party Review Program (formally known as the Accredited Persons Program) provides an alternative review pathway that many submitters overlook. Under Section 523 of the FD&C Act, FDA-recognized Third Party Review Organizations (3P510k ROs) can review certain 510(k) submissions and make SE recommendations to the FDA.

How It Works

1. Check eligibility. Approximately half of all 510(k) submissions are eligible for third-party review. The FDA maintains a searchable database of eligible device types at accessdata.fda.gov/scripts/cdrh/cfdocs/cfThirdParty/current.cfm. Generally, low-to-moderate risk Class II devices are eligible; high-risk, life-sustaining, and implantable devices are not.

2. Select an accredited review organization. The FDA maintains a current list of accredited 3P510k Review Organizations at accessdata.fda.gov/scripts/cdrh/cfdocs/cfthirdparty/accredit.cfm. You engage with the organization directly, pay their review fee (separate from the FDA user fee), and submit your 510(k) to them instead of directly to the FDA.

3. Third-party review. The review organization evaluates your submission using the same criteria the FDA would use. They may interact with the FDA during the review if questions arise.

4. FDA final determination. The review organization sends its recommendation (SE or NSE) to the FDA. The FDA then has 30 days to make a final determination. The FDA can accept the recommendation, conduct additional review, or reject the recommendation.

5. Notification. The review organization notifies you of the FDA's decision.

Benefits and Limitations

Benefits:

• Potentially faster total review time (the 30-day FDA decision goal after the third party completes its review can be faster than the standard 90-day review)
• May receive more interactive feedback during the review process
• Frees up FDA resources, which can indirectly benefit the broader review ecosystem

Limitations:

• Not all device types are eligible — check the eligibility database
• You pay both the FDA user fee and the third-party review organization's fee
• If the FDA disagrees with the third-party recommendation, additional review time is added
• The program has historically had low utilization (less than 2% of 510(k) submissions), partly due to limited awareness

Recent update: In November 2024, the FDA issued updated final guidance on the 510(k) Third Party Review Program, superseding previous guidance and expanding the program's scope.

When to consider third-party review: If your device is a straightforward, low-to-moderate risk Class II device with a clear predicate and standard testing, the third-party review pathway can be an efficient alternative — especially if FDA review queues are long. Check eligibility early in your planning process.

Special Designation Programs

Beyond the standard 510(k) pathway, two FDA programs can provide additional support and potentially faster review for qualifying devices.

Breakthrough Devices Program

The Breakthrough Devices Program provides expedited development, assessment, and review for devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. While this program is most commonly associated with PMA and De Novo submissions, it also applies to 510(k) devices.

Eligibility criteria (must meet one):

• Represents breakthrough technology
• No approved or cleared alternatives exist
• Offers significant advantages over existing approved or cleared alternatives
• Device availability is in the best interest of patients

Benefits:

• Prioritized review and increased interaction with FDA
• Opportunities for pre-submission engagement and sprint discussions
• Data development plan agreement
• Senior management involvement in the review process

How to apply: Submit a Breakthrough Device Designation request to the FDA. If granted, the designation applies throughout the premarket review process.

Safer Technologies Program (STeP)

The STeP program targets devices that offer significant safety improvements over existing treatments for conditions that are not life-threatening or irreversibly debilitating — a lower bar than the Breakthrough Devices Program.

When STeP applies: Your device significantly reduces the risk of serious adverse events, improves the benefit-risk profile through safety enhancements, or represents a meaningfully safer alternative to current standard of care for non-life-threatening conditions.

Benefits: Increased FDA interaction, potential for expedited review, and a dedicated FDA point of contact during the review process.

Practical tip: Both the Breakthrough Devices Program and STeP are voluntary and free to apply for. Even if you are unsure whether your device qualifies, the application process forces you to articulate your device's clinical value proposition — which strengthens your overall regulatory strategy.

Tips from Former FDA Reviewers

Insights from people who have sat on the other side of the table — reviewing 510(k) submissions at the FDA — are invaluable. Here are recurring themes from former FDA reviewers who now advise industry:

1. Make the Reviewer's Job Easy

Reviewers handle dozens of submissions simultaneously. A well-organized submission with clear cross-references, logical flow, and complete data gets reviewed faster and more favorably than a submission that forces the reviewer to hunt for information. Think of the reviewer as your audience — write for them.

2. Include a Completed RTA Checklist with Page References

Former reviewer Allison Komiyama recommends including a filled-out copy of the FDA's RTA acceptance checklist with your submission, noting the exact page number where each required element can be found. This allows the RTA screener to verify completeness in minutes rather than hours, and it dramatically reduces the chance of an erroneous RTA hold.

3. Never Submit "Promissory" Data

The era of "I promise" statements is over. You cannot submit a 510(k) with a note saying "sterilization validation will be completed before marketing" or "biocompatibility testing is in progress." All data must be final and included in the submission. Incomplete data is an automatic RTA rejection.

4. Consistency Is Everything

Reviewers check whether the Indications for Use statement on Form 3881, the intended use in the device description, the intended use in the SE comparison, the intended use in the labeling, and the intended use in the 510(k) summary all match — word for word. One former reviewer noted that inconsistency in the IFU across the submission is the single most common reason for immediate rejection.

5. Anticipate the Reviewer's Questions

For every claim you make, ask yourself: "If I were reviewing this, what would I ask?" For every difference between your device and the predicate, explain proactively why the difference does not raise new safety or effectiveness concerns. Leaving the reviewer to wonder invites AI requests.

6. Do Not Overwhelm with Irrelevant Data

Including 500 pages of raw test data without summaries, analysis, or clear acceptance criteria does not demonstrate thoroughness — it demonstrates disorganization. Provide concise summaries with clear pass/fail conclusions in the body of the submission, and attach full test reports as appendices for reference.

7. Your Device Description Must Stand on Its Own

A reviewer should be able to read your device description and fully understand what the device is, how it works, and what it is made of — without needing to look at your marketing materials, website, or test reports. The device description is the foundation that everything else in the submission rests on.

Tips for First-Time Submitters

If this is your first 510(k), the learning curve is steep. Here is what I tell every first-time submitter.

1. File a Pre-Sub First

This cannot be overstated. The Pre-Submission process is free, and the FDA provides written feedback within approximately 75 days. You will learn what testing they expect, whether your predicate is acceptable, and whether your regulatory strategy makes sense. Skipping the Pre-Sub to "save time" almost always costs more time in the long run through AI requests and resubmissions.

2. Do Not Underestimate Timelines

From the moment you decide to pursue a 510(k), expect 12–18 months to clearance for a typical Class II device. This includes:

• 2–3 months for Pre-Sub preparation and FDA feedback
• 3–6 months for testing (biocompatibility, performance, electrical safety, software V&V)
• 1–2 months for submission document preparation
• 3–9 months for FDA review (including potential AI requests)

3. Read the Predicate's 510(k) Summary

This is publicly available on the FDA database. Read it carefully. It tells you what testing the FDA found acceptable for a device like yours. It is the closest thing to an answer key that exists.

4. Use Recognized Consensus Standards

If FDA-recognized versions of standards apply to your device, cite them and test to them. This simplifies the review because the reviewer can quickly assess conformance rather than evaluating proprietary test methods.

5. Invest in Quality Labeling Early

Labeling is not an afterthought. Write your draft IFU and labeling early in the process, because:

• It forces you to articulate your intended use precisely
• It reveals gaps in your risk analysis (warnings, contraindications)
• It must be submitted with the 510(k), and rush-job labeling is a frequent deficiency

6. Budget Appropriately

A realistic budget for a first 510(k) (Class II device) includes:

Cost Category	Approximate Range
Regulatory consultant (if used)	$30,000 – $100,000+
Performance testing (bench, electrical, EMC)	$20,000 – $80,000
Biocompatibility testing	$15,000 – $60,000
Software V&V (if applicable)	$10,000 – $50,000
Sterilization validation (if applicable)	$15,000 – $40,000
Shelf life / packaging testing	$5,000 – $20,000
User fee (FY2026)	$6,517 – $26,067
Establishment registration (annual, FY2026)	$11,423
Total	$115,000 – $400,000+

These are order-of-magnitude estimates. Simple devices (non-sterile, no software, non-powered) are at the low end. Complex devices (active, sterile, software-driven, implantable) are at the high end or beyond.

7. Do Not Copy-Paste from the Predicate Summary

Your submission must describe your device, not the predicate. The predicate summary is a reference, not a template. Reviewers instantly recognize when a submission's device description is clearly copied from a predicate summary with minor edits.

8. Engage a Regulatory Consultant if Needed

There is no shame in getting help. Regulatory consultants who specialize in 510(k) submissions know the current reviewer expectations, common pitfalls, and can review your submission before filing. A good consultant can save you one or two AI rounds, which easily pays for their fee in time savings.

9. Maintain Meticulous Records

Every test report, every decision, every communication with the FDA should be documented and organized. If the FDA asks a question during review, you want to be able to respond within days, not weeks. A disorganized submission package leads to disorganized AI responses, which leads to more questions.

10. Understand What Clearance Does (and Does Not) Give You

A 510(k) clearance allows you to legally market the device. It does not:

• Give you patent protection
• Exempt you from state requirements or facility registration
• Exempt you from Quality System Regulation / QMSR compliance
• Exempt you from post-market requirements (MDR reporting, recalls, corrections)
• Guarantee reimbursement from payers
• Allow you to market outside the US (you need separate regulatory clearance for each market)

After Clearance: Post-Market Obligations

Receiving your 510(k) clearance letter is a milestone, but your regulatory obligations continue. Failure to meet post-market requirements can result in Warning Letters, consent decrees, import alerts, or even withdrawal of your device from the market.

Immediate Actions (Within 30 Days of Clearance)

• Register your establishment. If you have not already done so, register your manufacturing establishment with the FDA through the FDA Unified Registration and Listing System (FURLS). This requires paying the annual establishment registration fee ($11,423 for FY2026). Registration is required annually — it does not automatically renew.
• List your device. List your device in the FURLS system. You must include the 510(k) number, product code, device name, and other identifying information. Device listing must be updated annually and whenever you make changes.
• Apply your UDI. Assign a Unique Device Identifier to your device and submit device identification data to the Global Unique Device Identification Database (GUDID). UDI requirements vary by device class — Class II devices must have UDI on all device labels and packages.

Ongoing Compliance Requirements

• Quality Management System compliance (QMSR). As of February 2, 2026, the FDA's quality system requirements have transitioned from the Quality System Regulation (QSR) under 21 CFR Part 820 to the new Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. Key changes include:

  • The traditional Device Master Record (DMR), Device History Record (DHR), and Design History File (DHF) terminology has been replaced by the Medical Device File (MDF) concept from ISO 13485
  • The FDA's inspection approach has changed from the Quality System Inspection Technique (QSIT) to a new process described in Compliance Program 7382.850
  • Compliance with ISO 13485 alone is not sufficient — the QMSR includes additional FDA-specific requirements beyond ISO 13485
  • Supplier audit reports can now be inspected by the FDA under the QMSR framework
  • FDA inspections can occur at any time, and your first inspection often comes within 1–2 years of your first clearance

• Medical Device Reporting (MDR) under 21 CFR Part 803. You must report to the FDA:

  • Deaths or serious injuries that your device may have caused or contributed to — within 30 calendar days
  • Malfunctions that would be likely to cause or contribute to death or serious injury if the malfunction were to recur — within 30 calendar days
  • Events requiring remedial action to prevent an unreasonable risk of substantial harm to public health — within 5 working days

• Corrections and removals under 21 CFR Part 806. If you initiate a recall, correction, or removal of your device from the market, you must report it to the FDA. The FDA classifies recalls as Class I (most serious — reasonable probability of serious adverse health consequences or death), Class II (may cause temporary or medically reversible adverse health consequences), or Class III (not likely to cause adverse health consequences).

• 522 Postmarket Surveillance Studies. For certain devices, the FDA may order postmarket surveillance studies under Section 522 of the FD&C Act. This is more common for novel devices, implants, and devices where long-term performance data is limited. If the FDA orders a 522 study, you must submit a surveillance plan within 30 days and conduct the study as approved.

• Labeling updates. Keep your labeling current and consistent with your cleared indications for use. If new safety information emerges, update your labeling promptly.

• Change management. Evaluate all design changes, manufacturing changes, and labeling changes through your quality system to determine whether a new 510(k) is required. Document the rationale for your determination. Use the FDA's guidance document "Deciding When to Submit a 510(k) for a Change to an Existing Device" as your framework. When in doubt, file a new 510(k) or consult the FDA through a Pre-Submission.

• Annual establishment registration renewal. Pay the annual registration fee and renew your establishment registration each year between October 1 and December 31. Failure to renew can result in your establishment being listed as "not registered," which triggers regulatory action.

Frequently Asked Questions

How long does a 510(k) take?

Plan for 12–18 months from start to clearance for a typical first-time submission. The FDA's review goal is 90 MDUFA days, but calendar time including preparation, Pre-Sub, testing, and potential AI requests is much longer.

Can I sell my device while the 510(k) is under review?

No. You cannot commercially distribute the device until you receive the SE determination letter. You can, however, conduct clinical studies under an IDE (Investigational Device Exemption) if your study qualifies.

What if the FDA determines my device is NSE?

You have several options: submit a new 510(k) with a different predicate or additional data, pursue a De Novo classification request, pursue a PMA, or request a supervisory review of the NSE determination.

Can I use a competitor's device as a predicate?

Yes. Any legally marketed device can serve as a predicate, regardless of who manufactures it. You do not need permission from the predicate holder.

Do I need clinical data for a 510(k)?

It depends on the device type. Many Class II devices can be cleared with bench testing alone. Check the device-specific guidance document — if one exists for your product code, it will state whether clinical data is expected. When in doubt, ask in your Pre-Sub.

What is the difference between a 510(k) Summary and a 510(k) Statement?

A Summary is a detailed description of the basis for SE (made publicly available on the FDA database). A Statement is a brief certification that information supporting the SE finding will be made available to any person within 30 days of a request. Most companies file a Summary because it is standard practice and because a well-written summary demonstrates confidence in the submission.

Can I amend my 510(k) after submission?

You can submit amendments (additional information) in response to FDA requests. You can also proactively submit an amendment if you discover an error, though proactive amendments can reset the review clock. If the changes are significant, the FDA may ask you to withdraw and resubmit.

What is the Third Party Review Program, and should I use it?

The Third Party Review Program allows certain low-to-moderate risk devices to be reviewed by an FDA-accredited third-party organization instead of the FDA directly. The FDA then makes a final determination within 30 days of receiving the third party's recommendation. Approximately half of all 510(k) submissions are eligible, but fewer than 2% of submitters use the program. It can be advantageous if your device is straightforward and you want to avoid FDA queue delays. Check eligibility at accessdata.fda.gov/scripts/cdrh/cfdocs/cfThirdParty/current.cfm.

How much does a 510(k) cost in total?

The FDA user fee alone is $26,067 (standard) or $6,517 (small business) for FY2026. But the total cost including testing, regulatory consulting, and preparation typically ranges from $115,000 to $400,000+ for a first-time Class II device submission. Simple non-powered, non-sterile devices are at the low end; complex software-driven, sterile, or active devices are at the high end or beyond.

What changed with the QMSR transition in 2026?

Effective February 2, 2026, the FDA replaced the Quality System Regulation (QSR) with the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. If you already maintain an ISO 13485 quality management system, you are most of the way there — but QMSR includes additional FDA-specific requirements beyond ISO 13485. The traditional DMR/DHR/DHF terminology is replaced by the Medical Device File (MDF) concept, and the FDA has adopted a new inspection process. All manufacturers marketing devices in the US must comply with the QMSR.

Can I submit a 510(k) for a combination product?

Yes, but combination products (device + drug, device + biologic) involve additional complexity. The lead center (CDRH for device-led products, CDER for drug-led products, CBER for biologic-led products) determines the primary regulatory pathway. For device-led combination products, a 510(k) may be appropriate if the device component has a valid predicate. A Pre-Submission meeting is strongly recommended for any combination product.

What is the difference between a 510(k) clearance and FDA approval?

This is one of the most commonly confused distinctions. The FDA clears 510(k) devices — it finds them substantially equivalent to a predicate. The FDA approves PMA devices — it finds reasonable assurance of safety and effectiveness based on a more rigorous review. Using the wrong term in investor materials, press releases, or your submission itself signals a lack of regulatory understanding. Always say "510(k) clearance," never "510(k) approval."

Bottom Line

The 510(k) pathway is the workhorse of the US medical device regulatory system. It is well-defined, well-documented, and — when approached methodically — predictable. The companies that succeed with 510(k) submissions are the ones that invest in regulatory strategy up front (Pre-Sub, predicate selection, testing plan), execute thorough testing against recognized standards, and assemble clean, complete submissions that make the reviewer's job easy.

Do not rush the process. A submission that goes through clean is always faster than a submission that generates multiple rounds of AI requests. Invest the time to get it right the first time.

Start with the Pre-Sub. Know your predicate. Follow the guidance. Submit a complete package. That is the formula.